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          Streptococcus pneumoniae   (pneumococcus) is re-
sponsible for   >  1.5 million deaths worldwide and 
kills more people in the United States and Europe 
than any other vaccine-preventable disease (  1  ). 
Besides life-threatening invasive infections 
(meningitis, bacteremia, and pneumonia), it also 
causes millions of cases of otitis media in children. 
The highest incidence of invasive disease is de-
tected in children (mainly   <  2 yr of age) and in 
the elderly (mainly   >  65 yr of age). High mortal-
ity caused by pneumococcal infections occurs in 
the elderly as well as in young children living in 
developing countries, where every sixth child 
death is related to this pathogen (  2  ). 
  Because of this high medical need, great ef-
forts are being made to develop eff  ective vaccines 
for the prevention of pneumococcal diseases in 
both industrialized and developing countries. 
However, none of the current vaccines can ad-
dress the needs of both the elderly and children 
in all parts of the world. The challenges are di-
verse. Although capsular polysaccharides (CPSs) 
are proven to be eff  ective vaccine antigens, the 
existence of   >  90 diff  erent serotypes hinders the 
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  Pneumococcus is one of the most important human pathogens that causes life-threatening 
invasive diseases, especially at the extremities of age. Capsular polysaccharides (CPSs) are 
known to induce protective antibodies; however, it is not feasible to develop CPS-based 
vaccines that cover all of the 90 disease-causing serotypes. We applied a genomic approach 
and described the antibody repertoire for pneumococcal proteins using display libraries 
expressing 15  –  150 amino acid fragments of the pathogen  ’  s proteome. Serum antibodies of 
exposed, but not infected, individuals and convalescing patients identifi  ed the ANTIGENome 
of pneumococcus consisting of     140 antigens, many of them surface exposed. Based on 
several in vitro assays, 18 novel candidates were preselected for animal studies, and 4 of 
them showed signifi  cant protection against lethal sepsis. Two lead vaccine candidates, 
protein required for cell wall separation of group B streptococcus (PcsB) and serine/threonine 
protein kinase (StkP), were found to be exceptionally conserved among clinical isolates 
(  >  99.5% identity) and cross-protective against four different serotypes in lethal sepsis and 
pneumonia models, and have important nonredundant functions in bacterial multiplication 
based on gene deletion studies. We describe for the fi  rst time opsonophagocytic killing activity 
for pneumococcal protein antigens. A vaccine containing PcsB and StkP is intended for the 
prevention of infections caused by all serotypes of pneumococcus in the elderly and in children. 118 IMMUNE SELECTION OF NOVEL PNEUMOCOCCAL VACCINE ANTIGENS | Giefi  ng et al.
  In our eff  orts to comprehensively describe the human im-
mune response to pneumococcal protein antigens and, at the 
same time, select novel vaccine candidates, we aim to obtain 
crucial information about the natural human immune response 
during exposure to or infection by pneumococcus using sera 
from patients recovering from invasive disease, as well as 
healthy noncarrier adults exposed to the pathogen. Antigens 
that were expressed in vivo and induced antibodies in these 
donors were identifi  ed by using genomic surface display libraries, 
as previously described (  26, 27, 28  ). The process of preselect-
ing vaccine candidates from the ANTIGENome by in vitro 
epitope-based validation assays was described previously (  29  ). 
In earlier studies, novel antigens from the human pathogen 
  Staphylococcus aureus   were identifi  ed (  27  ), and one of those, 
IsdB, was selected for clinical testing based on animal protec-
tion data (  30  ) and is currently aimed for phase II studies for 
the prevention of nosocomial infections. 
  During these studies, we rediscovered the majority of the 
known protective pneumococcal proteins, but most impor-
tantly, we identifi  ed two novel types of pneumococcal vaccine 
antigens. These serve as lead candidates for the development of 
a vaccine that has the potential to address the needs of both the 
elderly and children by being exceptionally conserved among all 
serotypes, immunogenic in young children and the elderly, and 
capable of inducing bactericidal antibodies that can be used as 
in vitro markers of protection during future clinical studies. 
    RESULTS   
  Selection of human antibodies for antigen identifi  cation 
  Human serum samples for antigen screening were collected 
from 97 patients convalescing from invasive pneumococcal 
diseases, with an average age of 54 yr, and from 40 healthy 
adults between 20 and 45 yr of age. Sera were characterized 
for antipneumococcal IgG and IgA levels by ELISA using to-
tal lysates and culture supernatant fractions of a capsule-nega-
tive mutant   S. pneumoniae   TIGR4 strain. Individual samples 
showed a wide range of IgG and IgA reactivity against both 
bacterial lysate and culture supernatant fractions. For antigen 
discovery, we selected sera with high antipneumococcal titer 
from donors who recovered successfully (  Fig. 1 A  ).   Analysis 
of sera from healthy donors revealed that the highest anti-
pneumococcal antibody levels were mainly associated with 
adults who had young children living in the same household 
(  Fig. 1 B  ). Sera from parents (  n   = 9) showed signifi  cantly 
(P   <   0.05) higher ELISA reactivity than those from nonpar-
ents (  n   = 31), with median values of 10,236   ±   1,066 and 
7,802   ±   561 U for IgG, and 980   ±   156 and 373   ±   38 U for IgA, 
respectively. None of these serum donors were colonized by 
pneumococcus in the nasopharynx based on two indepen-
dent swab tests (taken 1 mo apart). 
  The ELISA reactivity of individual sera determined with 
lysate of the capsule-negative TIGR4 strain correlated well with 
the surface-staining intensity of encapsulated TIGR4 cells 
based on FACS analysis, demonstrating that the human sera 
had signifi  cant reactivity with pneumococcal surface antigens 
development of full-coverage vaccines. In addition, CPSs are 
not immunogenic enough in young children. 
  The 23-valent vaccine approved for adults shows effi   cacy 
only against bacteremia and meningitis in the elderly popula-
tion, but not against pneumonia, the most prevalent pneu-
mococcal disease of this age group (  3, 4  ). The conjugated 
7-valent vaccine, Prevnar, shows excellent effi   cacy against 
bacteremia and meningitis, which is the most frequent form 
of invasive pneumococcal disease in this age group, and also 
some eff  ect on pneumonia, otitis media, and colonization when 
caused by the seven included CPS serotypes (  5, 6, 7  ). However, 
pneumococcal serotype distribution varies from region to 
region in diff  erent parts of the world. In certain developing 
countries, Prevnar covers only one fourth of all disease-causing 
strains (  8, 9  ). Most importantly, serotype replacement induced 
by vaccination has already been clearly demonstrated in several 
clinical and surveillance studies (  10, 11, 12, 13  ). Thus, certain 
serotypes rarely detected in diseased children before vaccina-
tion now have major contributions, indicating that immune 
escape is taking place. Newer generations of pediatric conjugate 
vaccines including up to 13 diff  erent CPSs are in late-stage 
clinical development. However, these higher valency vaccines 
still only partially cover serotypes in developing countries, 
and the high manufacturing costs make it unaff  ordable for 
those with the greatest need. In the elderly, no clinical studies 
have shown improved effi   cacy and benefi  ts of conjugate 
vaccines so far. 
  A promising alternative approach for new-generation 
vaccines is the use of nonpolysaccharide antigens that are 
conserved among pneumococcal strains (  14  ). Thus, attention 
has focused recently on the development of recombinant 
protein  –  based subunit vaccines. Traditional approaches tar-
geted single candidate proteins based on their roles in bacte-
rial physiology and pathogenicity, such as PspA, PspC, and 
pneumolysin (  15, 16, 17, 18  ). Although these antigens show 
protective eff  ects in animal models of pneumococcal disease, 
the high sequence variability of PspA and PspC as well as the 
highly toxic nature of pneumolysin limit their use as vaccine 
candidates. Recently, more comprehensive technologies have 
been applied to identify novel antigens, taking advantage 
of complete bacterial genome sequences (  19, 20  ) (for review 
see reference   21  ). 
  In general, vaccine candidate antigens can be selected in 
silico by bioinformatic prediction, as demonstrated by reverse 
vaccinology (  22, 23, 24  ), but it is a labor-intensive endeavor 
and necessitates the expression of hundreds of recombinant 
proteins. Moreover, 25  –  40% of annotated genes in individual 
pathogen genomes are classifi  ed as hypothetical or with un-
known function that could result in excluding them as po-
tential vaccine candidates. In contrast, proteomic approaches 
select fewer antigens and have been shown to be highly suc-
cessful in selecting protective antigens (for review see refer-
ences   21, 25  ). However, the selection relies heavily on the 
expression of proteins in vitro, which may diff  er signifi  cantly 
from that under in vivo conditions with a requirement 
for virulence. JEM VOL. 205, January 21, 2008 
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FhuA (150  –  600 bp), as described previously (  28  ). Fusion of 
  S. pneumoniae   peptides to either of these two platform pro-
teins allows recognition of the surface-exposed peptides by 
cognate antibodies. 
  The surface display libraries were screened with six diff  er-
ent biotinylated Ig pools by MACS, as described previously (  27  ). 
12 MACS screens were performed, 6 each with the LamB 
and FhuA libraries. Of these, eight screens were performed with 
IgGs (four with each platform) and four were performed with 
IgAs (two with each platform). From the 12 library screens, 
we collected     10,000   E. coli   clones, as selected by human 
antibodies, and determined the DNA sequences of the pneumo-
coccal genome-derived inserts. These sequences allowed 
localization of the epitopes within annotated genes as well 
as in nonannotated regions of the TIGR4 genome. The insert 
sequences were aligned (examples shown in   Fig. 2 A  ), and 
all regions selected by at least two independent clones were 
verifi  ed for antibody reactivity by Western blot analysis of 
(unpublished data). Sera with the highest reactivity from both 
serum donor groups were further analyzed by Western blot-
ting to facilitate selection based on reactivity against multiple 
proteinaceous antigens (unpublished data). Finally, 20 sera 
were chosen for antigen identifi  cation from both donor 
groups. Four IgG (P1IgG, P2IgG, H1IgG, and H2IgG) and 
two IgA pools (P1IgA and H1IgA) were generated by affi   nity 
purifi  cation of pooled sera from fi  ve diff  erent donors (  Fig. 1  ). 
  Identifi  cation of the ANTIGENome of pneumococcus 
  The complete genome of   S. pneumoniae   TIGR4 was ran-
domly fragmented into average sizes of     70 or 300 bp either 
by DNase I treatment or sonication, respectively, as reported 
previously (  26  ). Two frame-selected libraries were generated 
by ligation of these fragments fi  rst into a frame-selection vec-
tor (  26, 27  ), followed by their transfer into display plasmids 
expressing the corresponding peptides by the   Escherichia coli   
outer membrane proteins LamB (for inserts   <  150 bp) and 
    Figure 1.         Characterization and selection of human sera for antigen identifi  cation.   Total  anti –  S. pneumoniae   IgG and IgA antibody levels were 
measured by ELISA using total bacterial lysate prepared from the TIGR4 capsule-negative strain as a coating antigen. 97 serum samples from (A) conva-
lescing patients with invasive diseases and (B) 40 healthy adults were analyzed; data are expressed as ELISA units calculated from absorbance at 405 nm. 
Sera selected for Ig purifi  cation and pooling are framed (triangle, Ig Pool1 for IgG and IgA; square, Ig Pool2 for IgG). Patients that suffered from meningi-
tis and pneumonia are indicated by open and closed symbols; those who died during the convalescence phase are marked with a cross. Healthy adults 
with children   <  10 yr of age in the household are shown with black dots, those with children between 10  –  12 yr of age are in gray, and those without 
children are circled.     120 IMMUNE SELECTION OF NOVEL PNEUMOCOCCAL VACCINE ANTIGENS | Giefi  ng et al.
immunogenic antigens (selected by at least 6 out of 12 screens) 
contained multiple epitopes in diff  erent regions of the proteins 
(  Fig. 2 A  ). Moreover, these were identifi  ed by both IgG and 
IgA antibodies from both patients and healthy exposed non-
colonized individuals, a strong indication for in vivo expres-
sion under disease and exposure at mucosal surfaces (  Table I  ). 
Several antigens  —  such as LytC, SP0667, SP1527, SP1891, and 
SP2027  —  were identifi  ed mainly by serum pools obtained 
from parents of young children, whereas others —  such as PcpA, 
CbpC, CbpI, and SP0107  —  were selected mainly by serum 
pools from patients in convalescent phase. 
  Prioritization among pneumococcal antigens by 
in vitro validation 
  The large number of antigens identifi  ed by the ANTIGE-
Nome technology prompted us to preselect for animal protec-
tion studies. Several in vitro assays that did not necessitate the 
generation of recombinant proteins but focused on important 
qualities of vaccine candidates were applied. The following 
criteria were addressed in these assays: (a) immunogenicity in 
humans, (b) surface exposure and/or secretion, (c) capability 
of inducing bactericidal antibodies, and (d) sequence conser-
vation. In addition, further selection was made based on in-
tellectual property claims. 
  We performed an extensive serological analysis of those 
identifi  ed epitopes that were devoid of signifi  cant homologies 
to human sequences. For this purpose, the immune reactivity of 
a representative clone using the screening Ig pools.   Through 
these analyses we identifi  ed 97 predicted open reading frames 
(ORFs) and 45 peptides encoded by nonannotated genomic 
regions (Table S1, available at http://www.jem.org/cgi/content/
full/jem.20071168/DC1). 
  By comparing the ANTIGENome with the complete 
proteome of   S. pneumoniae   TIGR4, we found an enrichment 
of antigens in the major cellular role categories: cell surface, 
cellular processes (virulence and pathogenicity), and protein 
fate (e.g., proteases;   Fig. 2 B  ). These three categories contrib-
uted to   >  50% of all identifi  ed annotated antigens. Impor-
tantly, one fi  fth of the immunogenic pneumococcal proteins 
did not have predictable signatures and were annotated as 
hypothetical or unknown function genes. 
  Importantly, we rediscovered the majority of known pro-
tective pneumococcal antigens  —  such as PspA (  15  ), PspC (  16  ), 
serine protease (  20  ), IgA1 protease (  31  ), and histidine triad 
proteins SP1003, SP1004, SP1174, SP1175 (  20, 32  ), NanA 
(  33  ), LytC (  20  ), and LytA (  34  )  —  with high frequency (  Table I  ).   
SP2216, a novel antigen that was annotated as a secreted 
45-kD protein (TIGR4 strain) or protein required for cell wall 
separation of group B streptococcus (PcsB; R6 strain), was 
identifi  ed as the most immunogenic protein, with 25% of all 
selected clones representing epitopes within this ORF. PcsB 
and two other proteins, PspA and PspC, which have been de-
scribed previously as highly immunogenic antigens (  15, 16  ), 
were selected in all 12 screens performed. Most of the highly 
    Figure 2.         Selection of antigenic pneumococcal proteins.   (A) Antigens of interest were identifi  ed by the reactivity of human serum antibodies with 
  E. coli   clones containing pneumococcal epitopes. Examples of antigenic regions are shown for two of the most frequently identifi  ed pneumococcal anti-
gens, PcsB and PspC. Protein domains were predicted using the PROSITE database (reference   61  ). ALA- and GLU-rich domains are rich in the amino acids 
alanine and glutamate, respectively. The CHAP domain is proposed to function in peptidoglycan hydrolysis; cysteine and histidine form part of the puta-
tive active site of the CHAP domain. Choline-binding repeat (CBR) is found in Gram-positive bacteria. (B) The   S. pneumoniae   TIGR4 proteome consists of 
all annotated proteins assigned to role categories. The ANTIGENome encompasses all antigenic proteins identifi  ed by bacterial surface display screens and 
confi  rmed to be immunogenic. Numbers refer to the percentage contribution of each category.     JEM VOL. 205, January 21, 2008 
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using total bacterial lysates prepared from   E. coli   clones display-
ing immunogenic pneumococcal epitopes. 90 hyperimmune 
sera were generated by immunization with single or pooled 
lysates of altogether 120   E. coli   clones derived from 90 diff  er-
ent antigens. Although it was possible to induce epitope-specifi  c 
antibodies with 75% of the injected   E. coli   clones based on 
peptide ELISA and Western blot analysis, not all positive 
mouse sera detected the corresponding protein by Western blot 
analysis of   S. pneumoniae   total lysate, suggesting that some pro-
teins were not expressed under in vitro growth conditions (un-
published data). Surface staining of encapsulated   S. pneumoniae   
TIGR4 cells by FACS analysis was observed with 43 sera 
(Table S2, available at http://www.jem.org/cgi/content/
full/jem.20071168/DC1). The 43 FACS-positive sera were 
further analyzed in an in vitro opsonophagocytic killing (OPK) 
assay using   S. pneumoniae   serotype 4 and 6B strains. Anti-
body- and complement-dependent killing was demonstrated 
with 31 sera (Table S2). Importantly, well-known protective 
pneumococcal antigens, such as PspA and PspC, were strongly 
positive, confi  rming the validity of this analysis. Both surface 
222 synthetic peptides, ranging in size from 9 to 26 aa and 
representing 136   S. pneumoniae   epitopes derived from 64 anno-
tated and 40 nonannotated ORFs, was determined by ELISA 
with the 20 individual human sera comprising the four Ig 
screening pools. The obtained results correlated well with 
the library screen data, as the most immunogenic peptides be-
longed to the most frequently selected antigens (e.g., PspA, 
SP0641, SP1175, PspC, and PcsB;   Fig. 3  )  . In addition, highly 
immunogenic epitopes from less frequently selected proteins 
were also detected (e.g., SP0564 and SP0454). In rare cases, fre-
quently selected long epitopes did not detect comparably high 
antibody levels with overlapping synthetic peptides, most prob-
ably because of the presence of conformational, discontinu-
ous epitopes. A more detailed peptide ELISA study with the 
50 most immunogenic peptides showed, for example, an age-
dependent increase in antibody levels among children and 
less reactivity in patients with unfavorable disease outcome 
(unpublished data). 
  Further characterization of antigens was facilitated by the 
generation of epitope-specific hyperimmune sera in mice 
    Table I.        Frequency of clone selection in genomic library screens 
ORF Common name Screens Hits FhuA LamB IgG IgA P H
SP2216 PcsB, secreted 45-kD protein (Usp45) 12 1766 1606 160 1374 392 662 1104
SP2190 PspC/CbpA 12 642 71 571 343 299 402 240
SP0117 PspA 12 272 75 197 158 114 183 89
SP0641 Serine protease, subtilase family 11 525 237 288 475 50 271 254
SP0664 Zinc metalloprotease ZmpB, putative 11 253 145 108 158 95 184 69
SP0071 IgA1 protease (Iga1) 10 164 26 138 70 94 105 59
SP1154 IgA1 protease (Iga2) 10 61 26 35 46 15 21 40
SP1174 Conserved domain protein 9 86 71 15 75 11 54 32
SP1527 Oligopeptide ABC transporter 9 64 7 57 37 27 4 60
SP1693 NanA 9 47 12 35 15 32 33 14
SP2201 CbpD 9 46 16 30 18 28 36 10
SP1004 Conserved hypothetical protein 9 43 38 5 29 14 26 17
SP1772 Cell wall surface anchor family protein 9 32 24 8 30 2 17 15
SP2136 PcpA 8 302 4 298 101 201 230 72
SP2099 Pbp1B 8 34 29 5 31 3 9 25
SP1175 Conserved domain protein 8 28 22 6 24 4 18 10
SP0107 LysM domain protein 7 219 218 1 215 4 185 34
SP1573 Lysozyme (LytC) 7 111 99 12 57 54 9 102
SP1003 Conserved hypothetical protein 7 38 36 2 31 7 23 15
SP0648     -galactosidase (BgaA) 71 1 38 1 0 1 4 7
SP0667 Pneumococcal surface protein, putative 6 327 327 0 235 92 85 242
SP0082 Cell wall surface anchor family protein 6 112 15 97 112 0 77 35
SP0377 CbpC 6 109 0 109 16 93 99 10
SP2027 Conserved hypothetical protein 6 54 2 52 34 20 6 48
SP0069 Choline-binding protein I (CbpI) 6 52 0 52 7 45 48 4
SP1891 Oligopeptide ABC transporter 6 28 7 21 13 15 2 26
SP1937 Autolysin (LytA) 6 19 4 15 4 15 16 3
SP0057     -    N    -acetylhexosaminidase (StrH) 6743 5 2 34
Screens represent the number of screens in which a given antigen was selected. Hits describe the total number of   E. coli   clones selected for one ORF; FhuA and LamB describe 
the total number of   E. coli   clones selected from the FhuA or LamB library, respectively; IgG and IgA describe the total number of   E. coli   clones selected with IgGs or IgAs; and 
P and H describe the total number of   E. coli   clones selected with antibodies derived from patients or healthy adult donors, respectively.122 IMMUNE SELECTION OF NOVEL PNEUMOCOCCAL VACCINE ANTIGENS | Giefi  ng et al.
patients with bacteremia and representing the 22 most impor-
tant serotypes of   S. pneumoniae   (1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 
9V, 12F, 14, 17F, 18C, 19A, 19F, 22F, 23F, 33F, 35A, and 35F). 
Based on this analysis, 10% of analyzed genes were absent in at 
least 15% of relevant clinical strains (e.g., SP0069, SP1154, and 
SP1330) and were not selected for in vivo studies. 
staining and OPK activity were considered as positive criteria 
for an antigen to be included among the list of candidates to 
be tested in animal models. 
  To select conserved antigens, we performed gene distribu-
tion studies by PCR using gene-specifi  c primers and genomic 
DNA isolated from 50 diff  erent clinical strains collected from 
    Figure 3.         Peptide ELISA with human sera.   Immune reactivities with individual human sera are shown for individual peptides representing the se-
lected antigenic regions. Serum samples correspond to the donors indicated in   Fig. 1  . Peptides are named by their corresponding ORF based on the  
S. pneumoniae   TIGR4 genome. Localization of epitopes is indicted by the position of the fi  rst and last amino acid residues of the peptides (  “  from aa  ”   and   “  to aa  ”  ). 
ORF names are as follows: SP, annotated; SPA, potential ORF in alternative reading-frame; and SPC, potential ORF on complementary strand. Scores for 
reactivity based on ELISA Units are as follows:   <  50 U = 0 (blue); 50  –  99 U = 1 (light yellow); 100  –  199 U = 2 (mustard yellow); 200  –  499 U = 3 (orange); 
  ≥  500 U = 4 (red); and not determined (white cells). The total reactivity score for each peptide is calculated with the 20 serum samples analyzed. HP, 
healthy adult pool; PP, patient pool.     JEM VOL. 205, January 21, 2008 
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and 4 novel ones (SP0368, SP0667, StkP, and PcsB), whereas 
the other antigens, such as SP0082, were clearly negative in 
these experiments (  Fig. 4 A  ; and Fig. S1 A, available at http://
www.jem.org/cgi/content/full/jem.20071168/DC1).   Impor-
tantly, we were able to show that protection was mainly 
aff  orded by antibodies, because passive immunization of naive 
animals with hyperimmune sera was eff  ective (Fig. S1 B). 
Using the i.p. challenge model with this   S. pneumoniae   sero-
type 6B strain (against which Prevnar provides complete pro-
tection), we did not observe signifi  cant protection with the 
remaining antigens; however, these are currently being tested 
in further animal models of pneumococcal disease (pneumonia 
and otitis media). 
  Characterization of the lead vaccine candidate antigens, 
PcsB and StkP 
  The four novel protective antigens were further character-
ized in a detailed gene conservation analysis. The SP0368 and 
SP0667 genes were missing from 8 and 10% of the 50 clinical 
strains tested, and the respective proteins showed variability 
in size (unpublished data). Thus, further animal testing focused 
on the two highly conserved candidates, StkP and PcsB. Because 
the N-terminal region of StkP contains the eukaryotic-type 
  Based on the in vitro validation results, 10 pneumococcal 
antigens fulfi  lling at least four out of the fi  ve validation crite-
ria were identifi  ed as the most promising vaccine candidates: 
SP0082, PspA, SP0368, SP0454, SP0609, SP0749, SP1891, 
SP2108, PspC, and PcsB. An additional 10 novel conserved 
candidates were selected for animal testing in spite of the lack 
of positive FACS data, as this could be attributed to insuffi   -
cient epitope-specifi  c antibodies in hyperimmune mouse sera 
or a lack of in vitro expression. These were SP0107, SP0564, 
SP0667, SP1374, SP1522, SP1527, serine/threonine protein 
kinase (StkP)/SP1732, SP2048, SP2051, and SP2092. With 
the exception of PspA and PspC, the known protective pneu-
mococcal antigens were excluded from this preselection. 
  Identifi  cation and characterization of protective 
vaccine candidates 
  The 20 genes encoding the selected antigens (full-length 
ORFs) were cloned from the   S. pneumoniae   TIGR4 strain and 
expressed as His-tagged proteins. For protection studies, mice 
were immunized with recombinant proteins and challenged 
i.v. or i.p. with a 200  ×   lethal dose of   S. pneumoniae   serotype 6B. 
Among the 20 antigens, 6 showed signifi  cant protection in these 
experiments: the 2 known protective antigens (PspA and PspC) 
    Figure 4.         Protection by PcsB and StkP in models of pneumococcal sepsis and pneumonia.   Mice were immunized with recombinant PcsBN and 
StkPC (with 1% ALUM) and challenged with   S. pneumoniae   as follows: (A) 10  5   CFU of the PJ-1259 strain i.p.; (B) 5   ×   10  6   CFU of the 6301 strain i.n.; (C) 10  5  
CFU of the WU2 strain i.n.; or (D) 6   ×   10  7   CFU of the EF3030 strain i.n. (A and B) Survival of animals was monitored for 10  –  14 d after challenge. Numbers 
of surviving mice are plotted as a percentage of the total. In A, P = 0.04 for StkP and PcsB, and P = 0.006 for PspA comparing time to death relative to the 
control group; in B, P   >   0.05. (C and D) Lung colonization of individual mice is shown at day 3 after challenge, indicating the median CFU per lung (hori-
zontal lines). Statistically signifi  cant differences based on the Mann-Whitney two-sample rank test are indicated. For all experiments, adjuvant-immunized 
mice served as negative controls.     124 IMMUNE SELECTION OF NOVEL PNEUMOCOCCAL VACCINE ANTIGENS | Giefi  ng et al.
between the PspA variants used for immunization (TIGR4, 
family 2/clade 3) and expressed by the challenge strain 6301 
(family 1/clade 1; PspA families and clades are according 
to Hollingshead et al. [  35  ]). The good protection seen with 
the PJ-1259 6B strain is well supported by the 95% identity 
to the TIGR4- and 6B-derived PspA proteins (both fam-
ily 2/clade 3). 
  To asses the eff  ect of immunization on lung colonization, 
two pneumonia models were set up with two diff  erent sero-
types. In the WU2 challenge model (serotype 3), both StkP 
and PcsB were capable of reducing the bacterial load in the 
lung 10 times relative to mock-immunized mice, similar to 
PspA (  Fig. 4 C  ). The two antigens were also eff  ective in re-
ducing lung infection by the EF3030 (serotype 19) strain. 
Immunization with PcsB typically resulted in 10 times re-
duced median bacterial load, whereas StkP was reproducible 
as eff  ective as Prevnar (containing serotype 19 CPS) and elim-
inated bacteria from the lung (below the detection limit) in 
50  –  60% of animals (both signifi  cantly diff  erent from the 
adjuvant control group; P   <   0.05;   Fig. 4 D  ). The partial pro-
tection seen for PspA might be again explained by its serovar-
iability in the two challenge strains relative to the one used 
for immunization (PspA family 1/clade 2 in WU2 and family 
1/clade 1 in EF3030) (  36, 37  ). 
serine threonine kinase domain with     35% identity to the 
corresponding human protein, we generated deletion mutants 
of StkP and used the C-terminal 314 aa residues for further 
protection studies (StkP-C). The C-terminal hydrophobic 
cysteine, histidine-dependent amidohydrolase/peptidase CHAP 
domain was removed from PcsB, which made expression and 
purifi  cation of the protein easier (PcsB-N). We observed that 
the two subdomains aff  orded the same level of protection 
as the respective full-length antigens (unpublished data). Im-
portantly, all epitopes identifi  ed in library screens for these 
antigens localized to the same regions, and the deleted parts 
were immunologically inert with human sera (even in recombi-
nant forms). Interestingly, the recombinant StkP-C was much 
more immunogenic with individual sera from patients and 
parents than could be concluded from the low number of hits 
in the primary library screen with pooled human serum anti-
bodies (unpublished data). 
  In an intranasal (i.n.) sepsis model, PcsB protected mice 
against death caused by an   S. pneumoniae   serotype 1 strain, 
whereas StkP immunization showed variable benefi  ts (at least 
delaying the time of death;   Fig. 4 B  ). No protection was 
observed with PspA in this model, possibly as a consequence 
of low amino acid identity (    35% not considering the 
C-terminal region with the invariant choline binding domain) 
    Figure 5.         PcsB and StkP are highly conserved antigens.   (A) Immunoblot analysis of pneumococcal isolates representing the serotypes contained 
in the 23-valent CPS vaccine. Bacterial lysates and culture supernatants were analyzed with hyperimmune mouse sera induced by recombinant PspA, StkP, 
and PcsB. (B) The amino acid sequence of StkP was determined in 58   S. pneumoniae   strains representing 48 different serotypes. The number and type 
of amino acid exchanges compared with a serotype 6B isolate are indicated. Protein domains were predicted using the PROSITE database (reference   61  ). 
The active site residue of the predicted kinase domain of StkP is indicated by a diamond.     JEM VOL. 205, January 21, 2008 
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sensitivity to penicillin, cephalosporins (e.g., ceftazidime), and 
vancomycin in vitro (  Fig. 6 A  ).   We observed greatly reduced 
or no disease-causing potential for       stkP   and       pcsB S. pneu-
moniae   strains, respectively, in a lethal challenge model when 
compared with the parental 6B WT strain (Fig. S2 B). In this 
model, deletion of   pspA   did not have an eff  ect on survival. 
  The obvious eff  ect on bacterial growth prompted us to 
study the morphology of the gene deletion mutant cells. Electron 
microscopy revealed a dramatic change in       pcsB   cells demon-
strating a defect in cell separation and/or septum formation. 
The normal diplococcus morphology disappeared; the daughter 
cells could not separate, resulting in cell conglomerates with 
division septa formed in diff  erent planes. The       stkP   cells dem-
onstrated an elongated shape and very few division septa sepa-
rating the daughter cells (  Fig. 6 B  ). 
  PcsB and StkP are immunogenic during pneumococcal 
infections and induce opsonophagocytic/bactericidal 
antibodies 
  Because these two antigens were identifi  ed using antibodies 
from adult donors, it was interesting for us to detect natural 
antibody responses against them in healthy children and fol-
low the development of specifi  c antibody levels as a function 
of age (repeated exposure). Using 88 sera obtained from healthy 
children aged 2 mo to 18 yr, we detected a wide range of 
IgG titers from almost undetectable to high levels (comparable 
with the highest values obtained with high titer sera from 
patients and parents). In sera from infants (  <  12 mo old) and 
  Detailed gene distribution analysis demonstrated that both 
genes were present in all of     100 clinical isolates that we col-
lected from patients with diff  erent invasive diseases or from 
nasopharyngeal carriers as analyzed by PCR (unpublished data). 
Similarly, the corresponding proteins were detected in all of 
the 60 tested clinical isolates representing 48 diff  erent serotypes 
based on Western blot analysis using hyperimmune mouse 
sera generated with recombinant proteins (  Fig. 5 A  ).   Impor-
tantly, the electrophoretic mobility, the strength of immune 
reactivity, and the size of the protein products were uniform for 
both StkP and PcsB, unlike for PspA. DNA sequence analyses 
of both genes from up to 60 strains with 48 distinct pneumo-
coccal serotypes revealed exceptionally high conservation. 
We detected only a single amino acid substitution for PcsB in 
only 1 out of 48 strains with diff  erent serotypes (A243S). StkP 
was sequenced from 60 strains encompassing the same 48 
  serotypes and was found to be highly conserved in 58 strains, 
with only up to three amino acid substitutions within one 
gene. Most of the amino acid variations occurred as substitutions 
with similar residues (  Fig. 5 B  ). The two strains carrying a variant 
  stkP   gene were lacking the third repeat of the penicillin-bind  ing 
protein and serine/threonine kinase  –  associated (PASTA) do-
main that had high sequence similarity to the second one. 
  The importance of PcsB and StkP in pneumococcal disease 
was demonstrated with gene deletion mutant pneumococci. 
The lack of either gene resulted in a strong reduction of bacte-
rial growth (Fig. S2 A, available at http://www.jem.org/cgi/
content/full/jem.20071168/DC1) and increased antibiotic 
    Figure 6.         Characterization of              pcsB   and                  stkP   gene deletion mutant strains.   (A) Antibiotic sensitivity was determined by the disc diffusion 
method in three independent experiments. The average increase in growth inhibition zone was expressed as a percentage relative to the WT; error bars 
represent standard deviations. (B) Transmission electron microscopic analyses of gene deletion strains     stkP   and     pcsB   KO and TIGR4 WT are shown. 
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B cell epitopes were identifi  ed that belonged to     140 ORFs 
and genomic regions not annotated as coding sequences. We 
rediscovered the majority of known protective proteins, such 
as PspA, PspC, and histidine triad proteins (  15, 16, 20, 34  ). 
Half of the annotated proteins of the pneumococcal ANTIG-
ENome belong to predicted or known surface proteins, viru-
lence factors, extracellular matrix binding proteins, and 
proteases. However, every fi  fth of them was encoded by hy-
pothetical or unknown function genes that could have been 
missed by approaches merely driven by prediction algorithms. 
Further analysis is needed to asses the value of nonannotated 
antigens in correcting gene assignment and discovery of novel 
very young children (12  –  24 mo old), the median ELISA val-
ues for PcsB were signifi  cantly lower (107 and 388 ELISA U, 
respectively) than in older age groups (    900 U;   Fig. 7  , 
bottom).   The StkP-specifi  c antibody levels showed a more 
continuous increase, with peak median value in the 8  –  12-yr-
old group (  Fig. 7  , top). 
  It has been well documented that specifi  c antipneumo-
coccal antibody levels induced by vaccination of children 
with polysaccharide-based vaccines correlate well with opso-
nophagocytic/bactericidal antibodies, whereas in elderly people, 
antibody levels overestimate the protection. Therefore, it was 
of paramount importance to develop a reliable in vitro func-
tional assay to measure the bactericidal activity of antibodies 
induced by the novel vaccine candidate antigens. The in vitro 
OPK assay used for the prioritization of antigens (Table S2) 
was further optimized to make it suitable for future clinical 
studies as a surrogate marker. We have developed a repro-
ducible and reliable assay with the human HL60 cell line, 
baby rabbit complement, and rabbit and human sera. We were 
able to detect surface staining with rabbit hyperimmune sera 
specifi  c for PcsB and StkP by FACS analysis (  Fig. 8 A  ) and 
OPK activity (  Fig. 8 B  ).   Importantly, OPK activity could 
also be shown for affi   nity-purifi  ed antigen-specifi  c human 
antibodies induced during exposure to pneumococcus (un-
published data). 
    DISCUSSION   
  To our knowledge, this is the most comprehensive study de-
scribing the antibody repertoire induced in the human host 
during pneumococcal disease and exposure. There are many 
reports on antipolysaccharide antibodies in vaccinated or dis-
eased individuals, or in healthy children, but very few on species 
common antigens. The immunogenicity studies investigating 
protein-specifi  c antibodies have focused on virulence factors 
and/or vaccine candidates (  38, 39, 40, 41, 42  ). For the rational 
design of a novel protein-based vaccine, we fi  rst studied the 
human immune response against pneumococcal proteins on a 
global scale using genomic surface display libraries that served 
as tools for the expression of all potential epitopes. The serum 
antibodies from patients successfully recovering from invasive 
pneumococcal diseases or from parents of young children 
  allowed us to identify those bacterial proteins that were expressed 
in the host during disease or mucosal exposure, respectively. 
To avoid bias from abundant anti-CPS antibodies, a capsule-
negative mutant strain was used for immune characterization 
of our serum collection. We found a good correlation between 
antipneumococcal nonpolysaccharide-specifi  c antibody levels 
and disease severity among patients with invasive disease. In 
the healthy adult group, high antibody levels were indicative 
of exposure to pneumococcus by small children living in the 
same household. Because none of these high titer parents 
were carriers, the antibodies could be considered potentially 
protective against nasopharyngeal colonization, the fi  rst step 
toward disease. 
  By fi  ngerprinting of the pneumococcal proteome with 
preselected pooled IgG and IgA antibodies, several hundred 
    Figure 7.         StkP and PcsB antigens are immunogenic in young children.   
88 sera obtained from children not suffering from any infectious disease 
at the time of sampling were analyzed for antipneumococcal IgG levels 
by ELISA using recombinant proteins as coating antigens. Individual data 
points are indicated in six age subgroups (  n   = 8  –  21) for StkP (top) and 
PcsB (bottom). Data are expressed as ELISA units (OD, 405 nm) at 1:1,000 
serum dilutions; horizontal lines represent medians.     JEM VOL. 205, January 21, 2008 
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  At the same time, some of the current vaccine candidates, 
such as PsaA and pneumolysin, were not among the ANTI-
GENome. In the case of PsaA, this could be explained by the 
low antibody titers against this protein present in sera selected 
for antigen identifi  cation (unpublished data). It is also possible 
that certain protective antigens are not immunogenic in the 
human host during infection or contain mainly structural ep-
itopes that cannot be expressed in the genomic surface ex-
pression libraries. 
  We found a large overlap between proteins identifi  ed by 
the two diff  erent serum donor groups, suggesting that in gen-
eral the same antigens were expressed during invasive disease 
and mucosal exposure. Additional detailed serological anal-
ysis of the epitopes with immune reagents from diff  erent 
  cohorts of donors may identify   “  missing  ”   antibodies in 
susceptible individuals (e.g., very young children or acutely 
diseased elderly people) and further characterize host immune 
responses to pneumococcus under diff  erent disease condi-
tions and exposure. 
  A series of in vitro epitope-based validation assays were 
applied to preselect vaccine candidates for animal testing. 6 out 
of 20 pneumococcal antigens (cloned from TIGR4) showed 
signifi  cant cross-protection in a stringent mouse model of 
lethal sepsis (with a human serotype 6B isolate). These were 
the two best-characterized pneumococcal vaccine candidates, 
PspA and PspC, and four novel antigens, SP0368, SP0667, 
StkP, and PcsB. The functions of SP0368, a choline-binding 
protein, and SP0667, pneumococcal surface protein, have 
not been revealed yet. PcsB in   S. pneumoniae   and its homo-
logues from   Streptococcus agalactiae   and   mutans   were previ-
ously shown to be involved in important bacterial survival 
mechanisms, maintenance of cell morphology, and growth 
(  43, 44, 45, 46  ). We substantiated these fi  ndings by successfully 
creating gene deletion strains for the fi  rst time and, thus, 
demonstrating that   pcsB   is not an essential gene for pneumo-
coccus. We observed greatly reduced in vitro growth and 
complete loss of virulence that might be caused by a lack of 
in vivo growth. Electron microscopic analysis confi  rmed pre-
vious light microscopy fi  ndings with strains expressing low 
levels of PcsB (  43, 44  ) and demonstrated drastic changes in 
cell morphology and aberrant division septum formation. 
The predicted CHAP domain at the C terminus of PcsB is 
indicative for its involvement in hydrolysis of peptidoglycan, 
whereas no such activity could be shown for any of the homo-
logues nor by us with recombinant or native PcsB (unpub-
lished data). We delineated the protective epitopes to the 
N-terminal immunogenic region. Interestingly, glucan-binding 
protein B, the homologue from   S. mutans  , was shown to protect 
from caries (  47, 48  ). 
  StkP possesses amino acid sequence homology to serine/
threonine kinases with a suggested important role in cell  –  cell 
signaling and competence triggering, as well as resistance to 
various stress conditions, by acting as a transcriptional regula-
tor (  49, 50, 51 52  ). Several activities are associated with this 
protein, such as autophosphorylation and phosphorylation of 
phosphoglucosamine mutase, which is important for cell wall 
short reading frames. Importantly, as this antigen selection is 
not biased by the often artifi  cial abundance or lack of protein 
expression in bacteria grown under in vitro conditions (  25  ), 
we also detected immunogenic epitopes that were derived 
from proteins not expressed by in vitro grown pneumococci. 
    Figure 8.         Antigen-specifi  c immune sera show surface staining and 
OPK activity.   (A) Surface staining of   S. pneumoniae   serotype 4 DS2341-
94 cells was performed with hyperimmune rabbit sera specifi  c for StkP 
and PcsB and PE-conjugated secondary antibodies. The signal resulting 
from staining with preimmune sera is shown in light gray; StkP and PcsB 
specifi  c signals are shown in dark gray. (B) Bactericidal activity of protein-
specifi  c antibodies as determined in an in vitro OPK assay.   S. pneumoniae  
serotype 4 DS2341-94 cells were preincubated with rabbit hyper-
immune (HI) or with their respective preimmune (PI) sera at a dilution 
of 1:1,000 in the presence of baby rabbit complement. HL60 phagocytic 
and pneumococcal cells were used at a 400:1 ratio. Data are expressed 
as the percentage of bacterial survival relative to the initial CFU at 
time 0. The average of three experiments is shown; error bars represent 
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to PspA (TIGR4 derived). The most striking observation was 
the highly signifi  cant protection by StkP immunization in the 
EF3030-induced pneumonia model that was comparable with 
the eff  ect of the conjugated Prevnar vaccine. 
  A further very important aspect of developing novel pro-
tein-based antibacterial vaccines is to apply in vitro functional 
antibody assays and defi  ne correlates of protection that can be 
used as surrogate markers in clinical development. Based on 
the characteristics of PcsB and StkP (surface localization, im-
portant in vivo function, and a high level of conservation), 
both opsonophagocytic and neutralizing antibodies are ex-
pected to contribute to cross-protection, mainly because of 
antibodies based on results of serum transfer experiments. 
Our detection of OPK activity induced by PcsB and StkP 
immunization represents the fi  rst in vitro functional antibody 
assay for pneumococcal protein antigens. It remains to be es-
tablished in additional preclinical and clinical studies whether 
OPK antibodies induced by protein antigens will suffi   ce as 
surrogate markers of protection. However, it is fi  rmly estab-
lished that vaccine effi   cacy against pneumococcus can be cor-
related with serum levels of opsonizing antibodies induced by 
polysaccharide antigens (  56  ). 
  Based on the results presented in this study, a subunit 
vaccine using a combination of antigens is being developed. 
Because the lead vaccine candidates, StkP and PcsB, are 
immunogenic in both the elderly and very young children 
and expressed during invasive disease, as well as during colo-
nization and exposure, it is possible that the same vaccine can 
address the needs of both target populations. The serotype-
independent expression of the antigens suggests that the 
broad spectrum of disease-causing serotypes detected in the 
elderly, the distinct distribution of pediatric strains in devel-
oping countries, and the emergence of nonvaccine strains in 
developed countries can be also addressed. 
  MATERIALS AND METHODS 
  Bacterial strains and growth conditions.     Clinical isolates were collected 
by the Swedish Institute for Infectious Disease Control. The WU2 (serotype 3) 
and EF3030 (serotype 19) strains were provided by D. Briles (University of 
Alabama at Birmingham, Birmingham, AL), the 6301 (serotype 1) strain was 
provided by I. Jonsdottir (Landspitali University Hospital, Reykjavik, Iceland), 
the DS2341-94 strain was provided by E. Ades (Centers for Disease Control 
and Prevention, Atlanta, GA), and the serotype 4 unencapsulated strain was 
provided by E. Tuomanen (St. Jude Children  ’  s Research Hospital, Memphis, 
TN). Bacteria were grown in Todd-Hewitt broth (BBL; Becton Dickinson) 
plus 0.5% yeast extract (THY) or in brain-heart infusion broth for   S. pneumoniae   
6301 at 37  °  C in an atmosphere of 5% CO  2  . 
  Human serum samples and their characterization.     Sera from 96 
patients were obtained at the Karolinska University Hospital in a study ap-
proved by the Ethical Committees of the Karolinska University Hospital and 
the Karolinska Institute. Sera from healthy adults were collected during rou-
tine occupational health checks (leftover samples were used with informed 
consent) or were from existing serum collections (Austrian Red Cross, Vienna, 
Austria). 88 sera were collected from children while they were hospitalized 
for noninfectious disorders (samples were saved after completed routine blood 
tests and handled according to institutional regulations at the Bethesda Childrens  ’  s 
Hospital, Budapest, Hungary). 
  Antibodies against   E. coli   proteins were removed from the pooled sera 
as described previously (  26  ). For screening, Igs were purifi  ed by affi   nity 
synthesis (  50  ). In accordance with our fi  ndings, gene deletion 
D39 and 23477 mutant strains were found to be less virulent 
in mice. However, no in vitro growth defect was observed, 
in contrast to our data generated with two different strains 
(TIGR4 and PJ-1259 6B). Our electron microscopic studies 
revealed an altered cell shape and a defect in forming division 
septa. StkP contains a characteristic structural signature: four 
copies of the PASTA domain that is also present in penicillin-
binding proteins (  53  ). Although StkP does not contain pre-
dictable signal peptide sequences, it is expressed on the bacterial 
surface (  Fig. 8 A  ) (  49, 53  ). We concluded that the C-terminal 
PASTA domains are the immunogenic region of the protein, 
which induces protective immune responses in animals. 
  PspA, PspC, and PcsB were the most frequently selected 
antigens in the genomic library screens. Highly immunogenic 
proteins are suspected to be fake targets of the immune re-
sponse, with protective ones being prone to genetic variability 
as exploited by pathogens to escape host defense. Indeed, PspA 
and PspC are highly variable, which is thought to be a result of 
immune pressure (  35, 54  ). In this context, it is a very signifi  cant 
fi  nding that the most immunogenic pneumococcal protein 
in our screens, PcsB, is exceptionally conserved among the 
diff  erent serotypes, with almost 100% amino acid identity. 
A similar high level of sequence conservation was found for StkP. 
The extent of sequence diversity of PspA and PspC (  35, 54  ), 
as well as of SP0368 and SP0667 (unpublished data), would 
necessitate several clade variants to be included in a broad 
coverage vaccine. Because it is likely that a combination of 
several diff  erent antigens is necessary to develop an eff  ective 
antipneumococcal protein-based vaccine (  55  ), the selection 
of highly conserved, species-common proteins seems to 
be crucial. 
  Genetic variability of antigens under immune pressure by 
the host is not limited to epitope diversity but can also lead to 
the complete loss of an antigen or phase variants. Targeting 
bacterial proteins that fulfi  ll important nonredundant roles in 
in vivo survival and growth, instead of virulence factors with 
often redundant functions, minimizes the possibility of nega-
tive selection and strain replacement induced by vaccination. 
Our studies suggested important functions for PcsB and StkP, 
but not for PspA, in bacterial growth, antibiotic sensitivity, 
and in vivo survival that could also explain the high degree of 
gene conservation observed. 
  A major requirement for viable vaccine candidates for the 
prevention of pneumococcal disease is the demonstration of 
protective eff  ects against several of the major disease causing 
serotypes. The limitation of the diff  erent animal models that 
try to mimic human disease can be compensated for by testing 
multiple in vivo models. Moreover, results generated in widely 
used models allow comparison of diff  erent candidates consid-
ered for vaccine development. In addition to the 6B sero-
type  –  induced i.p. sepsis model, the lead vaccine antigens PcsB 
and StkP were also tested by i.n. challenge of mice with the 
sepsis-causing serotype 1 and pneumonia-inducing serotype 3 
(WU2) or 19F (EF3030) strains (  37  ). Both proteins were ef-
fective in all models with equal or superior protection relative JEM VOL. 205, January 21, 2008 
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type 1 strain (6301;     5   ×   10  6   CFU) in a volume of 40   μ  l under injection 
anesthesia (Ketamin/Rompun). Antigen-specifi  c total IgG levels were de-
termined for all sera of immunized mice. Only experimental groups with 
suffi   ciently high antibody levels (end-point ELISA titer   >  1:10,000) were 
evaluated. In serum transfer experiments, mice received 150   μ  l of mouse se-
rum i.p. 1  –  3 h before challenge. In the pneumonia model, CD-1 mice were 
challenged with strains WU2 (    10  5   CFU) or EF3030 (    5   ×   10  7   CFU), and 
the lungs were removed at day 3 after challenge and homogenized in PBS. 
Samples were serially diluted and plated on blood agar plates, and viable 
counts were determined after overnight incubation. A nonparametric test 
(Mann-Whitney) was used to compare numbers of CFU (log10) or time to 
death between groups. P   ≤   0.05 was considered statistically signifi  cant. 
  Generation of pneumococcal gene deletion strains.     Gene deletion 
strains were generated by competence stimulatory peptide  –  induced transfor-
mation of   S. pneumoniae   strains TIGR4 and PJ-1259 (  58, 59  ). The gene re-
placement cassettes  —  the kanamycin gene (  60  ) surrounded by 1-kb fl  anking 
regions of the target genes  —  were generated by ligation-mediated PCR. For 
transformation, 2   ×   10  6   pneumococcal logarithmic growing cells were incu-
bated in competence medium with 0.5   μ  g of PCR-generated linear DNA 
for 3 h at 37  °  C. Transformants were selected on blood agar containing 250 
  μ  g/ml kanamycin. 
  Electron microscopy.     WT,       stkP  , and       pcsB   mutant cells of   S. pneu-
moniae   strains TIGR4 and PJ-1259 were fi  xed with 2.5% glutaraldehyde in 
PBS (pH 7.4) for 2 h on ice and for 1 h at room temperature, fi  lled into cellulose 
capillary tubes (0.2 mm in diameter), fi  xed with 2% OsO  4   in Sorensen  ’  s buf-
fer for 90 min, and dehydrated with increasing concentrations of ethanol. 
Samples were embedded in epoxy resin (Agar 100), and thin sections (60  –  80 nm) 
were cut with an ultramicrotome (Ultracut S; Leica) mounted on copper 
grids, contrasted by uranyl acetate and lead citrate, and examined at 80 kV in 
an electron microscope (JEM-1210; JEOL). Images were acquired using a 
digital camera (Morada) for the wide-angle port of the TEM and analySIS 
FIVE software (all from Soft Imaging System). 
  Online supplemental material.     Table S1 lists all pneumococcal antigens 
(TIGR4 strain annotation) that were identifi  ed by genomic library screen-
ing, indicating the total number of clones identifi  ed in the diff  erent screens 
with IgG and IgA pools as well as their immunogenic regions. Table S2 sum-
marized the results of surface staining and OPK assay obtained with epitope-
specific mouse sera. Fig. S1 depicts the selection of novel protective 
pneumococcal vaccine candidates in a mouse sepsis model. Fig. S2 shows the 
characterization of       pcsB   and       stkP   gene deletion mutant strains regarding 
their in vitro growth and in vivo virulence. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20071168/DC1. 
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chromatography and labeled with biotin (  27  ). Peptide serology was per-
formed with biotin-labeled synthetic peptides coated on streptavidin-cov-
ered ELISA plates. Serum antibodies were detected by horseradish peroxidase 
(HRPO)  –  conjugated anti  –  human IgG secondary antibodies (SouthernBiotech). 
Antigen-specifi  c antibodies in sera of children were analyzed by recombi-
nant protein  –  coated ELISA plates and HRPO-conjugated anti  –  human sec-
ondary antibodies. 
  Gene distribution and sequence analysis of pneumococcal antigens.   
  Oligonucleotides were designed for selected ORFs to amplify PCR prod-
ucts of approx. 1,000 bp. For gene distribution, PCR with genomic DNA 
of   S. pneumoniae   isolates was performed using Taq polymerase (Invitrogen). 
The full-length   stkP   and   pcsB   genes were amplifi  ed with primers matching 
the sequences in the   S. pneumoniae   TIGR4 genome fl  anking the correspond-
ing ORFs, using the Expand High Fidelity PCR kit (Roche). 
  Surface staining of bacteria.     Bacteria from the early logarithmic growth 
phase were collected and washed twice in HBSS. Approximately 10  5   CFU 
in 100   μ  l HBSS, 0.5% BSA were incubated with mouse or rabbit sera at 0.5 
and 2% fi  nal concentrations for 60 min at 4  °  C before detection with FITC-
labeled goat anti  –  mouse IgGs (F(ab    )  2   fragment specifi  c; Dako) or PE-con-
jugated goat anti  –  rabbit IgG (H+L; Beckman Coulter) antibodies. After 
fi  xation with 2% paraformaldehyde, surface staining was detected by a fl  ow 
cytometer (Cytomics FC500; Beckman Coulter), and data were analyzed 
using analysis software (CXP; Beckman Coulter). 
  OPK assays.     For the analysis of epitope-specifi  c mouse hyperimmune sera 
(  27  ), a mouse macrophage cell line (RAW264.7) and   S. pneumoniae   strains 
TIGR4 or PJ-1259 (human isolate from a nasopharyngeal carrier, serotype 
6B; ratio of phagocytes to bacteria = 20:1) were used in the presence of 
guinea pig complement. For the analysis of rabbit and human sera, DS2341-
94 and the human HL60 cell line (diff  erentiated for 5  –  6 d with 100 mM di-
methylformamide [  57  ]) were used at a ratio of 400:1 in the presence of baby 
rabbit complement. Bacteria were washed in HBSS and     10  5   CFU/40   μ  l 
(for RAW264.7) and 5   ×   10  3   CFU/80   μ  l (for HL60) incubated with 50   μ  l 
of mouse serum and 10   μ  l of guinea pig complement or with 2   μ  l of 1:10 
diluted rabbit/human serum and 10   μ  l of baby rabbit complement in a total 
volume of 100   μ  l for 60 min at 4  –  6  °  C. Serum-opsonized bacteria were 
mixed with 100   μ  l of phagocytic cells and incubated for 60 min at 37  °  C. An 
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